Sigilon Brings on Eli Lilly’s Moller as Chief Scientific Officer
David Moller has joined Sigilon Therapeutics to become the company’s chief scientific officer. Moller comes to the Cambridge, MA, drug developer from Eli Lilly (NYSE: LLY), where he was vice president of business development for emerging technology and innovation. Last year, Sigilon raised $23.5 million in a Series A financing round to bring its technology for encapsulating therapeutic proteins into clinical testing.
Underwriters and Partners
Xpertise: Watch + Learn
Sponsored · Whitepaper
Protecting Valuable Life Science Assets & Equipment: Monitoring Solutions
Remain compliant and ensure optimal productivity
XiltriX
Sponsored · Whitepaper
Monitoring Solutions for Pharma-CRO/CMO Partnerships to Maintain Quality & Timelines
Implementing electronic solutions for risk mitigation
XiltriX
Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes
From Our Advertisers
Charles River 3rd World Congress: Delivering Therapies to the Clinic Faster
Join us Sept. 23-24
Charles River
Finding the formula for biohealth success in Wisconsin
A unique collaboration fosters innovation at Forward BIOLABS
Wisconsin Economic Development Corporation